Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?

Area of Science:

• Cancer immunotherapy
• Cellular therapy
• Tumor immunology

Background:

• Immune effector cell (IEC) therapy, especially chimeric antigen receptor (CAR) T-cell therapy, has demonstrated success in hematological malignancies.
• Clinical application of CAR T-cell therapy in solid tumors is nascent, facing significant hurdles.
• Preclinical data suggest potential, but clinical translation requires overcoming specific challenges.

Purpose of the Study:

• To review the challenges of CAR T-cell therapy in solid tumors from a clinical perspective.
• To summarize current clinical trials investigating CAR T-cell therapy for solid tumors.
• To highlight novel strategies aimed at improving CAR T-cell efficacy in solid tumors.

Main Methods:

• Review of published clinical trials involving CAR T-cell therapy for solid tumors.
• Analysis of challenges including on-target off-tumor toxicity, target identification, tumor trafficking, and immune evasion.
• Summary of ongoing preclinical and clinical research addressing these obstacles.

Main Results:

• CAR T-cell therapy has shown efficacy in CD19+ B cell malignancies and multiple myeloma.
• Clinical data for CAR T-cell therapy in solid tumors are limited.
• Key challenges identified include toxicity, target selection, tumor infiltration, and resistance to immune evasion.

Conclusions:

• CAR T-cell therapy holds potential for solid tumors but requires overcoming significant clinical challenges.
• Ongoing research focuses on innovative modifications to enhance safety and effectiveness.
• Further clinical investigation is crucial for advancing CAR T-cell therapy in solid tumor treatment.